Eli Lilly to buy Merida Biosciences in deal worth up to $2.88 billion
18 Articles
18 Articles
Lilly to Buy Merida for $2.88 Billion for Autoimmune Expansion
Eli Lilly & Co. plans to buy Merida Biosciences Inc. for as much as $2.88 billion in cash to expand in autoimmune and allergic diseases, part of an effort to build beyond the weight-loss and diabetes markets that made it the largest pharmaceutical company in the world.
The pharmaceutical company spends up to $2.88 billion on the acquisition of the biotech company Merida Biosciences. The purchase is financed with the billions from the chipping boom.
Eli Lilly continues its rapid pace of acquisitions and has announced an agreement to buy the biotechnology company Merida Biosciences for up to US$2.87 billion, strengthening the pharmaceutical company's immunology portfolio. Exclusive content for subscribers. For full access, follow the link to the article and register.
Coverage Details
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
